New FDA-Approved Broad Companion Diagnostic (CDx) for Solid Tumors with Medicare Coverage1
FoundationOne CDx helps inform treatment decisions, with insights specific to each patient’s cancer. Results from a single tissue sample (FFPE) identify multiple biomarkers to save time and tissue compared with sequential single-gene testing.
When submitting specimens to Foundation Medicine, please include the following items in the FoundationOne CDx Specimen Kit:
- Appropriate specimen per FoundationOne CDx Specimen Instructions labeled with two patient-specific identifiers
- Completed Test Requisition Form
- Copy of recent pathology/cytology reports
Easy-to-understand test results are available online or via fax in less than 14 days. Reports match cancer patients’ molecular information with targeted therapies, immunotherapies, and clinical trials to expand treatment options.